For patients with locally advanced HNSCC, combined irradiation and inhibition of the EGFR with a chimeric monoclonal antibody (cetuximab) is an approved treatment alternative to concurrent, cisplatin-based radiochemotherapy (RCTx) [[3], [4], [5]]. Here, EGFR is linked to head and neck squamous cell carcinoma.